MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.53 USD | -1.36% |
|
-9.68% | +56.22% |
| Jun. 20 | Top Premarket Gainers | MT |
| Jun. 17 | Transcript : Molecular Partners AG Presents at TD Cowen 2nd Annual Radiopharmaceutical Innovation Summit, Jun-17-2024 10:40 AM |
| Sales 2024 * | 10M 11.15M | Sales 2025 * | 18.66M 20.8M | Capitalization | 202M 225M |
|---|---|---|---|---|---|
| Net income 2024 * | -65M -72.45M | Net income 2025 * | -61M -67.99M | EV / Sales 2024 * | 20.2 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 10.8 x |
| P/E ratio 2024 * |
-3.12
x | P/E ratio 2025 * |
-3.28
x | Employees | 168 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.27% |
More Fundamentals
* Assessed data
More news
Latest transcript on Molecular Partners AG
More recommendations
More press releases
| 1 day | -1.36% | ||
| 1 week | -9.68% | ||
| Current month | -9.68% | ||
| 1 month | +52.57% | ||
| 3 months | +65.32% | ||
| 6 months | +53.68% | ||
| Current year | +56.22% |
1 week
6.43
7.63
1 month
4.4012.70
Current year
3.3212.70
1 year
3.3212.70
3 years
3.3232.04
5 years
3.3232.04
10 years
3.3232.04
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 52 | 04-11-22 | |
Patrick Amstutz
FOU | Founder | 49 | 04-11-22 |
Michael Pitzner
CMP | Compliance Officer | - | 22-10-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Burns
CHM | Chairman | 76 | 17-10-30 |
Steven Holtzman
BRD | Director/Board Member | 70 | 14-09-18 |
Vito Palombella
BRD | Director/Board Member | 61 | 20-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 6.53 | -1.36% | 18,516 |
| 24-07-03 | 6.62 | -5.43% | 6,789 |
| 24-07-02 | 7 | -4.76% | 40,133 |
| 24-07-01 | 7.35 | +1.66% | 9,144 |
| 24-06-28 | 7.23 | +2.53% | 4,510 |
Delayed Quote Nasdaq, July 05, 2024 at 04:00 pm EDT
More quotes
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
2024-08-26
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
6.09
CHF
Average target price
10.35
CHF
Spread / Average Target
+69.95%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +16.61% | 122B | |
| +17.75% | 112B | |
| +17.23% | 25.91B | |
| -24.11% | 19.33B | |
| -18.56% | 16.17B | |
| -18.47% | 15.6B | |
| -47.75% | 14.65B | |
| +57.35% | 14.34B | |
| +5.62% | 14B |
- Stock Market
- Equities
- MOLN Stock
- MOLN Stock
